Profile
Gregor K.
Mirow is Chief Financial Officer, Chief Operating Officer, and Chief Productivity Officer for Greenovation Biotech GmbH.
Most recently, he was Senior Vice President of Operations for Micromet, Inc. He was Chief Operating Officer and Chief Financial Officer of Micromet AG.
Previously, he held executive directorships at the Rentschler Pharmaceuticals Group and ReGen Therapeutics Plc.
He has 20 years of professional experience in the life science industry.
Dr. Mirow received an MD from the Technical University, Munich in 1986 and an MBA in Finance from The Wharton School at the University of Pennsylvania in 1989.
Former positions of Gregor K. Mirow
Companies | Position | End |
---|---|---|
Eleva GmbH
Eleva GmbH BiotechnologyHealth Technology Eleva GmbH develops biotechnology products and services. It offers Moss-aGal, Moss-GBA, Moss-FH, contract development and production, developmental pipeline, and technology transfer. The company was founded by Ralf Reski and Gunther Neuhaus in 1999 and is headquartered in Heilbronn, Germany. | President | 2011-06-08 |
ReGen Therapeutics Plc
ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Director/Board Member | 1999-04-29 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Chief Operating Officer | - |
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | Director of Finance/CFO | 2006-05-04 |
Training of Gregor K. Mirow
Technische Universität München | Doctorate Degree |
University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | Health Technology |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
Eleva GmbH
Eleva GmbH BiotechnologyHealth Technology Eleva GmbH develops biotechnology products and services. It offers Moss-aGal, Moss-GBA, Moss-FH, contract development and production, developmental pipeline, and technology transfer. The company was founded by Ralf Reski and Gunther Neuhaus in 1999 and is headquartered in Heilbronn, Germany. | Health Technology |
ReGen Therapeutics Plc
ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Gregor K. Mirow